4-N-tert-butyloxycarbonylamino-N-benzyloxycarbonyl-L-cis-proline | 281666-44-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-N-tert-butyloxycarbonylamino-N-benzyloxycarbonyl-L-cis-proline
• 英文别名: (2S,4S)-1-(Benzyloxycarbonyl)-4-(tert-butoxycarbonylamino)pyrrolidine-2-carboxylic acid；(2S,4S)-4-[(2-methylpropan-2-yl)oxycarbonylamino]-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid
• CAS: 281666-44-2
• 化学式: C₁₈H₂₄N₂O₆
• 分子量: 364.398
• InChiKey: DDWOAECQYPSHMZ-KBPBESRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-N-tert-butyloxycarbonylamino-N-benzyloxycarbonyl-L-cis-proline 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 水 为溶剂， 生成 (2S,4S)-4-[(2-methylpropan-2-yl)oxycarbonylamino]pyrrolidin-1-ium-2-carboxylate
  参考文献：
  名称：

  Synthesis of Alanine and Proline Amino Acids with Amino or Guanidinium Substitution on the Side Chain

  摘要：

  Competitive binding of peptides containing basic amino acids to disrupt or prevent the Tat-TAR interaction could result in diminished transcription as well as translation and hence constitutes an alternative way of controlling HN replication. Therefore, we synthesized guanidinium and amino containing amino acids, based on a proline or an alanine scaffold. The introduction of the guanidinium moiety was best accomplished using 1H-pyrazole-1-carboxamidine hydrochloride, with Pmc used for its protection. The absence of racemization, maintained throughout the whole synthesis, was confirmed by chiral purity determination. These building blocks were smoothly incorporated into oligopeptides, which proved their suitability for use in a combinatorial approach for selecting TAR binding ligands. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(00)00123-x
• 作为产物：
  描述：

  1-苄基2-甲基(2S,4S)-4-{[[((叔丁氧基)羰基]氨基]吡咯烷-1,2-二羧酸酯 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 4-N-tert-butyloxycarbonylamino-N-benzyloxycarbonyl-L-cis-proline
  参考文献：
  名称：

  HIV整合酶抑制剂的发现和合成：开发有效的和口服可生物利用的N-甲基嘧啶酮。

  摘要：

  人类1型免疫缺陷病毒（HIV-1）编码三种对于病毒复制必不可少的酶：逆转录酶，蛋白酶和整合酶。后者负责将病毒基因组整合到人类基因组中，因此代表了对AIDS进行化学疗法干预的诱人靶标。基于这种机制的药物尚未获得批准。在我们的实验室中发现苄基-二羟基嘧啶-羧酰胺是一类新型的，代谢稳定的药物，对HIV整合酶链转移步骤具有有效的抑制作用。进一步的努力导致了基于结构相关的N-Me嘧啶酮骨架的非常有效的化合物。该系列中最有趣的化合物之一是2-N-Me-吗啉代衍生物27a，其显示在血清存在下细胞中的CIC95为65 nM。该化合物在三种临床前物种中均具有良好的药代动力学特性，并且在几种抗筛选试验中未显示任何责任。

  DOI：

  10.1021/jm0704705

文献信息

• Thienopyrazole Derivative Having PDE7 Inhibitory Activity
  申请人：Inoue Hidekazu

  公开号：US20090131413A1

  公开（公告）日：2009-05-21

  To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R 1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R 2 is methyl; R 3 is a hydrogen atom; and R 4 is a group: —CONR 5 R 6 (in which any one of R 5 and R 6 is a hydrogen atom)].

  为了提供选择性抑制PDE 7的噻唑吡啶衍生物，从而增强细胞cAMP水平。因此，该化合物可用于治疗各种疾病，如过敏性疾病、炎症性疾病或免疫性疾病。该化合物是由以下式子(I)表示的噻唑吡啶化合物：[其中，特别地，R1是环己基、环庚基或四氢吡喃基；R2是甲基；R3是氢原子；R4是一个基团：—CONR5R6（其中R5和R6中的任何一个是氢原子）]。
• THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1775298B1

  公开（公告）日：2013-03-20
• MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS
  申请人：RQX PHARMACEUTICALS, INC.

  公开号：US20180327367A1

  公开（公告）日：2018-11-15

  Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
• US6800434B2
  申请人：——

  公开号：US6800434B2

  公开（公告）日：2004-10-05
• US8901315B2
  申请人：——

  公开号：US8901315B2

  公开（公告）日：2014-12-02